4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reaffirmed at Weiss Ratings
Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report report published on Saturday morning,Weiss Ratings reports. FDMT has been the topic of several other research reports. Chardan Capital restated a “buy” rating and set a $39.00 target price on shares of 4D Molecular […]
More Stories
7.7 Magnitude Earthquake Strikes Myanmar and Thailand, Causing Widespread Destruction
A powerful 7.7 magnitude earthquake struck Southeast Asia on March 28, 2025, causing widespread destruction and fatalities in Myanmar and...
Corient Private Wealth LLC Purchases 1,374 Shares of Olin Co. (NYSE:OLN)
Corient Private Wealth LLC grew its position in shares of Olin Co. (NYSE:OLN – Free Report) by 6.8% during the...
Swiss National Bank Has $2.15 Million Stock Holdings in NETSTREIT Corp. (NYSE:NTST)
Swiss National Bank lifted its position in NETSTREIT Corp. (NYSE:NTST – Free Report) by 5.7% in the fourth quarter, Holdings...
Tumwater Wealth Management LLC Takes Position in Alphabet Inc. (NASDAQ:GOOGL)
Tumwater Wealth Management LLC bought a new position in Alphabet Inc. (NASDAQ:GOOGL – Free Report) during the 4th quarter, Holdings...
Corient Private Wealth LLC Has $860,000 Position in Commerce Bancshares, Inc. (NASDAQ:CBSH)
Corient Private Wealth LLC boosted its holdings in shares of Commerce Bancshares, Inc. (NASDAQ:CBSH – Free Report) by 8.8% in...
HighTower Advisors LLC Purchases 2,186 Shares of Alaska Air Group, Inc. (NYSE:ALK)
HighTower Advisors LLC boosted its holdings in shares of Alaska Air Group, Inc. (NYSE:ALK – Free Report) by 20.6% in...